- Home
- EDRY vs ANTX Comparison
EDRY vs ANTX Comparison
Compare EDRY & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDRY | ANTX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9M | 34.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | EDRY | ANTX |
|---|---|---|
| Price | $13.63 | $1.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 3.6K | ★ 73.8K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,384,447.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.94 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.60 | $1.01 |
| 52 Week High | $16.14 | $1.60 |
Technical Indicators
Market Signals| Indicator | EDRY | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 40.60 |
| Support Level | $12.48 | $1.04 |
| Resistance Level | $13.38 | $1.12 |
| Average True Range (ATR) | 0.36 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 75.66 | 37.50 |
Price Performance
Historical ComparisonAbout EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.